BIGG

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline

Agarwal, Arnav; Agoritsas, Thomas; Aertgeerts, Bert; Coyac, Frederic; Farhoumand, Pauline Darbellay; Demaine, Andrew; Fog Heen, Anja; Foroutan, Farid; Guyatt, Gordon H; Jha, Vivekanand; Li, Sheyu; Machuve, Edward,; Nagler, Evi; Ponte, Belen; Rayner, Daniel; Tunnicliffe, David J; Vandvik, Per Olav; Zeng, Xiaoxi.

BMJ; e080257 (), 2024

What is the impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on survival and on cardiovascular and kidneyoutcomes for adults living with chronic kidney disease (CKD)? Few therapies slow kidney disease progression and improve long term prognosis for adults living with CKD. SGLT-2 inhibitors ha...

Insuficiencia Renal Crónica/diagnóstico, Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico, Progresión de la Enfermedad, Albuminuria/orina, Tasa de Filtración Glomerular, Insuficiencia Renal Crónica/tratamiento farmacológico

Texto completo

Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline

Clinical question: What is the role of medical cannabis or cannabinoids for people living with chronic pain due to cancer or non-cancer causes? Current practice: Chronic pain is common and distressing and associated with considerable socioeconomic burden globally. Medical cannabis is increasingly used t...